373 related articles for article (PubMed ID: 23555300)
1. Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis.
Cui J; Stahl EA; Saevarsdottir S; Miceli C; Diogo D; Trynka G; Raj T; Mirkov MU; Canhao H; Ikari K; Terao C; Okada Y; Wedrén S; Askling J; Yamanaka H; Momohara S; Taniguchi A; Ohmura K; Matsuda F; Mimori T; Gupta N; Kuchroo M; Morgan AW; Isaacs JD; Wilson AG; Hyrich KL; Herenius M; Doorenspleet ME; Tak PP; Crusius JB; van der Horst-Bruinsma IE; Wolbink GJ; van Riel PL; van de Laar M; Guchelaar HJ; Shadick NA; Allaart CF; Huizinga TW; Toes RE; Kimberly RP; Bridges SL; Criswell LA; Moreland LW; Fonseca JE; de Vries N; Stranger BE; De Jager PL; Raychaudhuri S; Weinblatt ME; Gregersen PK; Mariette X; Barton A; Padyukov L; Coenen MJ; Karlson EW; Plenge RM
PLoS Genet; 2013 Mar; 9(3):e1003394. PubMed ID: 23555300
[TBL] [Abstract][Full Text] [Related]
2. A longitudinal genome-wide association study of anti-tumor necrosis factor response among Japanese patients with rheumatoid arthritis.
Honne K; Hallgrímsdóttir I; Wu C; Sebro R; Jewell NP; Sakurai T; Iwamoto M; Minota S; Jawaheer D
Arthritis Res Ther; 2016 Jan; 18():12. PubMed ID: 26776603
[TBL] [Abstract][Full Text] [Related]
3. Low rates of adherence for tumor necrosis factor-α inhibitors in Crohn's disease and rheumatoid arthritis: results of a systematic review.
Fidder HH; Singendonk MM; van der Have M; Oldenburg B; van Oijen MG
World J Gastroenterol; 2013 Jul; 19(27):4344-50. PubMed ID: 23885145
[TBL] [Abstract][Full Text] [Related]
4. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
van Herwaarden N; den Broeder AA; Jacobs W; van der Maas A; Bijlsma JW; van Vollenhoven RF; van den Bemt BJ
Cochrane Database Syst Rev; 2014 Sep; (9):CD010455. PubMed ID: 25264908
[TBL] [Abstract][Full Text] [Related]
5. Genome-wide association analysis of anti-TNF drug response in patients with rheumatoid arthritis.
Umiċeviċ Mirkov M; Cui J; Vermeulen SH; Stahl EA; Toonen EJ; Makkinje RR; Lee AT; Huizinga TW; Allaart R; Barton A; Mariette X; Miceli CR; Criswell LA; Tak PP; de Vries N; Saevarsdottir S; Padyukov L; Bridges SL; van Schaardenburg DJ; Jansen TL; Dutmer EA; van de Laar MA; Barrera P; Radstake TR; van Riel PL; Scheffer H; Franke B; Brunner HG; Plenge RM; Gregersen PK; Guchelaar HJ; Coenen MJ
Ann Rheum Dis; 2013 Aug; 72(8):1375-81. PubMed ID: 23233654
[TBL] [Abstract][Full Text] [Related]
6. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
[TBL] [Abstract][Full Text] [Related]
7. Lack of replication of genetic predictors for the rheumatoid arthritis response to anti-TNF treatments: a prospective case-only study.
Suarez-Gestal M; Perez-Pampin E; Calaza M; Gomez-Reino JJ; Gonzalez A
Arthritis Res Ther; 2010; 12(2):R72. PubMed ID: 20423481
[TBL] [Abstract][Full Text] [Related]
8. National and regional dose escalation and cost of tumor necrosis factor blocker therapy in biologic-naïve rheumatoid arthritis patients in US health plans.
Joyce AT; Gandra SR; Fox KM; Smith TW; Pill MW
J Med Econ; 2014 Jan; 17(1):1-10. PubMed ID: 24131136
[TBL] [Abstract][Full Text] [Related]
9. Differences in biologic dose-escalation, non-biologic and steroid intensification among three anti-TNF agents: evidence from clinical practice.
Moots RJ; Haraoui B; Matucci-Cerinic M; van Riel PL; Kekow J; Schaeverbeke T; Davis A; Tedeschi MA; Freundlich B; Chang DJ; Singh A
Clin Exp Rheumatol; 2011; 29(1):26-34. PubMed ID: 21345289
[TBL] [Abstract][Full Text] [Related]
10. Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis.
Maxwell JR; Potter C; Hyrich KL; ; Barton A; Worthington J; Isaacs JD; Morgan AW; Wilson AG
Hum Mol Genet; 2008 Nov; 17(22):3532-8. PubMed ID: 18713756
[TBL] [Abstract][Full Text] [Related]
11. Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis.
Morales-Lara MJ; Cañete JD; Torres-Moreno D; Hernández MV; Pedrero F; Celis R; García-Simón MS; Conesa-Zamora P
Joint Bone Spine; 2012 Dec; 79(6):591-6. PubMed ID: 22480748
[TBL] [Abstract][Full Text] [Related]
12. Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients.
Carter CT; Changolkar AK; Scott McKenzie R
J Med Econ; 2012; 15(2):332-9. PubMed ID: 22168788
[TBL] [Abstract][Full Text] [Related]
13. A genome-wide association study identifies a new locus associated with the response to anti-TNF therapy in rheumatoid arthritis.
Julià A; Fernandez-Nebro A; Blanco F; Ortiz A; Cañete JD; Maymó J; Alperi-López M; Fernández-Gutierrez B; Olivè A; Corominas H; Erra A; Acosta-Colman I; Alonso A; López-Lasanta M; Tortosa R; Tornero J; Marsal S
Pharmacogenomics J; 2016 Apr; 16(2):147-50. PubMed ID: 25896534
[TBL] [Abstract][Full Text] [Related]
14. Tumor necrosis factor blocker dose escalation among biologic naïve rheumatoid arthritis patients in commercial managed-care plans in the 2 years following therapy initiation.
Bonafede MM; Gandra SR; Fox KM; Wilson KL
J Med Econ; 2012; 15(4):635-43. PubMed ID: 22332705
[TBL] [Abstract][Full Text] [Related]
15. Lack of association of variants previously associated with anti-TNF medication response in rheumatoid arthritis patients: results from a homogeneous Greek population.
Zervou MI; Myrthianou E; Flouri I; Plant D; Chlouverakis G; Castro-Giner F; Rapsomaniki P; Barton A; Boumpas DT; Sidiropoulos P; Goulielmos GN
PLoS One; 2013; 8(9):e74375. PubMed ID: 24040234
[TBL] [Abstract][Full Text] [Related]
16. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
Ollendorf DA; Klingman D; Hazard E; Ray S
Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
[TBL] [Abstract][Full Text] [Related]
17. Ankylosing spondylitis and rheumatoid arthritis: serum levels of TNF-α and Its soluble receptors during the course of therapy with etanercept and infliximab.
Schulz M; Dotzlaw H; Neeck G
Biomed Res Int; 2014; 2014():675108. PubMed ID: 24783218
[TBL] [Abstract][Full Text] [Related]
18. [New drugs and treatment strategies for rheumatoid arthritis].
Fantini F
Recenti Prog Med; 2003 Sep; 94(9):361-79. PubMed ID: 12942798
[TBL] [Abstract][Full Text] [Related]
19. Preliminary evaluation in rheumatoid arthritis activity in patients treated with TNF-alpha blocker plus methotrexate versus methotrexate or leflunomide alone.
Wisłowska M; Jakubicz D
Rheumatol Int; 2007 May; 27(7):641-7. PubMed ID: 17235556
[TBL] [Abstract][Full Text] [Related]
20. Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany.
Li N; Betts KA; Messali AJ; Skup M; Garg V
Clin Ther; 2017 Aug; 39(8):1618-1627. PubMed ID: 28729087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
